Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

Protalix BioTherapeutics, Inc. PLX, an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX–102), a drug candidate for the treatment of adult patients with Fabry disease.

Fabry disease is a rare enzyme deficiency that afflicts 1 in 40,000 to 60,000 people worldwide. Patients with Fabry are unable to break down the fatty substance globotriaosylceramide (Gb3), leading to accumulation of Gb3 in the blood vessels and symptoms including impaired blood circulation, end-organ failure, and increased risk of heart attack and stroke.

"The resubmission of the BLA represents a significant milestone for Protalix and we believe it has meaningful potential for patients and families affected by Fabry disease,” said Dror Bashan, Protalix's President and Chief Executive Officer. "Together with Chiesi, we are committed to continuing to work with the FDA toward our goal of achieving regulatory approval and making PRX–102 available to patients with this rare disease in the United States."

A Step Closer To Important Treatment

Protalix develops treatments from its proprietary plant cell-based expression system, ProCellEx®.  Its drug candidate PRX-102 is a modified recombinant α–Galactosidase–A enzyme that would allow the Fabry disease patient to digest Gb3. This drug is part of Protalix’s novel PEGylated enzyme replacement therapy (ERT) treatment.

The resubmission of the BLA for drug candidate PRX-102 involves a rigorous and comprehensive set of data on the therapy. Protalix is confident moving forward, as it was the first company to receive Food and Drug Administration (FDA) approval of a protein produced through a plant cell-based expression system. Now it is collaborating with the rare disease unit of the Chiesi Group, an Italian-based therapeutic development company, to develop and commercialize PRX-102 for the treatment of Fabry disease.

“We believe it is important to deliver a potential new treatment option," said Giacomo Chiesi, head of Chiesi Global Rare Diseases, commenting on the resubmission of the BLA. "Together with Protalix, we thank the investigators and study participants who have made reaching this milestone possible and have supported our joint commitment to bringing this new treatment option to the Fabry patient community."

Protalix anticipates the FDA will review the resubmission within the next 6 months.

Other companies looking to develop treatments for Fabry disease include Avrobio Inc. AVRO, Freeline Therapeutics Holdings PLC FRLN, and Sangamo Therapeutics Inc. SGMO.

To learn more about Protalix BioTherapeutics, click here.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured Photo by Chinnapong on Shutterstock.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksSmall CapGeneralPartner ContentProtalix BioTherapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!